Literature DB >> 29712865

Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.

Aaron Seo1,2, Orna Steinberg-Shemer3,4, Sule Unal5, Silvia Casadei1,2, Tom Walsh1,2, Fatma Gumruk6, Stavit Shalev7, Akiko Shimamura8, Nurten Ayse Akarsu9, Hannah Tamary3,4, Mary-Claire King10,2.   

Abstract

BRCA1 is essential for repair of DNA double-strand breaks by homologous recombination, and hence for survival. Complete loss of its function is lethal during early embryonic development. Patients who are compound heterozygous for BRCA1 truncating mutations and missense alleles that retain some DNA repair capacity may survive, albeit with very high risk of early onset breast or ovarian cancer and features of Fanconi anemia. However, a mechanism enabling survival of patients homozygous for BRCA1 truncating mutations has not been described. We studied two unrelated families in which four children presented with multiple congenital anomalies and severe chromosomal fragility. One child developed T cell acute lymphocytic leukemia (ALL), and a second child developed neuroblastoma. Each of the four children was homozygous for a nonsense mutation in BRCA1 exon 11. Homozygosity for the nonsense mutations was viable thanks to the presence of a naturally occurring alternative splice donor in BRCA1 exon 11 that lies 5' of the mutations. The mutations did not affect the alternative splice site, but transcription from it produced an in-frame BRCA1 message with deletion of 3,309 bp. The translated BRCA1 protein was only 40% of normal length, but with intact N- and C-terminal sequences. These patients extend the range of BRCA1-related phenotypes and illustrate how naturally occurring alternative splicing can enable survival, albeit with severe consequences, of otherwise lethal genotypes of an essential gene.

Entities:  

Keywords:  BRCA1; DNA repair; RNA splicing; chromosomal fragility

Mesh:

Substances:

Year:  2018        PMID: 29712865      PMCID: PMC5960323          DOI: 10.1073/pnas.1801796115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.

Authors:  Tom Walsh; Silvia Casadei; Ming K Lee; Christopher C Pennil; Alex S Nord; Anne M Thornton; Wendy Roeb; Kathy J Agnew; Sunday M Stray; Anneka Wickramanayake; Barbara Norquist; Kathryn P Pennington; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

2.  Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.

Authors:  T Ludwig; D L Chapman; V E Papaioannou; A Efstratiadis
Journal:  Genes Dev       Date:  1997-05-15       Impact factor: 11.361

3.  Inherited Mutations in Women With Ovarian Carcinoma.

Authors:  Barbara M Norquist; Maria I Harrell; Mark F Brady; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Sarah S Bernards; Silvia Casadei; Qian Yi; Robert A Burger; John K Chan; Susan A Davidson; Robert S Mannel; Paul A DiSilvestro; Heather A Lankes; Nilsa C Ramirez; Mary Claire King; Elizabeth M Swisher; Michael J Birrer
Journal:  JAMA Oncol       Date:  2016-04       Impact factor: 31.777

4.  Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity.

Authors:  Michael Y Zhang; Siobán B Keel; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Amanda C Watts; Colin C Pritchard; Stephen J Salipante; Michael R Jeng; Inga Hofmann; David A Williams; Mark D Fleming; Janis L Abkowitz; Mary-Claire King; Akiko Shimamura
Journal:  Haematologica       Date:  2014-09-19       Impact factor: 9.941

5.  The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.

Authors:  R Hakem; J L de la Pompa; C Sirard; R Mo; M Woo; A Hakem; A Wakeham; J Potter; A Reitmair; F Billia; E Firpo; C C Hui; J Roberts; J Rossant; T W Mak
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

6.  Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.

Authors:  Sarah L Sawyer; Lei Tian; Marketta Kähkönen; Jeremy Schwartzentruber; Martin Kircher; Jacek Majewski; David A Dyment; A Micheil Innes; Kym M Boycott; Lisa A Moreau; Jukka S Moilanen; Roger A Greenberg
Journal:  Cancer Discov       Date:  2014-12-03       Impact factor: 39.397

Review 7.  Pathophysiology and management of inherited bone marrow failure syndromes.

Authors:  Akiko Shimamura; Blanche P Alter
Journal:  Blood Rev       Date:  2010-04-24       Impact factor: 8.250

8.  Comparison of chromosome breakage in non-mosaic and mosaic patients with Fanconi anemia, relatives, and patients with other inherited bone marrow failure syndromes.

Authors:  John H Fargo; Andrzej Rochowski; Neelam Giri; Sharon A Savage; Susan B Olson; Blanche P Alter
Journal:  Cytogenet Genome Res       Date:  2014-09-11       Impact factor: 1.636

9.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Authors:  Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson
Journal:  N Engl J Med       Date:  2016-07-06       Impact factor: 91.245

10.  Breast-cancer risk in families with mutations in PALB2.

Authors:  Antonis C Antoniou; Silvia Casadei; Tuomas Heikkinen; Daniel Barrowdale; Katri Pylkäs; Jonathan Roberts; Andrew Lee; Deepak Subramanian; Kim De Leeneer; Florentia Fostira; Eva Tomiak; Susan L Neuhausen; Zhi L Teo; Sofia Khan; Kristiina Aittomäki; Jukka S Moilanen; Clare Turnbull; Sheila Seal; Arto Mannermaa; Anne Kallioniemi; Geoffrey J Lindeman; Saundra S Buys; Irene L Andrulis; Paolo Radice; Carlo Tondini; Siranoush Manoukian; Amanda E Toland; Penelope Miron; Jeffrey N Weitzel; Susan M Domchek; Bruce Poppe; Kathleen B M Claes; Drakoulis Yannoukakos; Patrick Concannon; Jonine L Bernstein; Paul A James; Douglas F Easton; David E Goldgar; John L Hopper; Nazneen Rahman; Paolo Peterlongo; Heli Nevanlinna; Mary-Claire King; Fergus J Couch; Melissa C Southey; Robert Winqvist; William D Foulkes; Marc Tischkowitz
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

View more
  16 in total

1.  Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2).

Authors:  Lisa J McReynolds; Kajal Biswas; Neelam Giri; Shyam K Sharan; Blanche P Alter
Journal:  Cancer Genet       Date:  2021-10-04

2.  Brca1 mutations in the coiled-coil domain impede Rad51 loading on DNA and mouse development.

Authors:  J J Krais; N Johnson
Journal:  Mol Cell Oncol       Date:  2020-07-20

3.  Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.

Authors:  Katharina Keupp; Stephanie Hampp; Annette Hübbel; Monika Maringa; Sarah Kostezka; Kerstin Rhiem; Anke Waha; Barbara Wappenschmidt; Roser Pujol; Jordi Surrallés; Rita K Schmutzler; Lisa Wiesmüller; Eric Hahnen
Journal:  Mol Genet Genomic Med       Date:  2019-07-25       Impact factor: 2.183

4.  Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.

Authors:  Gabriel S Macedo; Barbara Alemar; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2019-04-29       Impact factor: 1.771

5.  The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability.

Authors:  Adalgeir Arason; Bjarni A Agnarsson; Gudrun Johannesdottir; Oskar Th Johannsson; Bylgja Hilmarsdottir; Inga Reynisdottir; Rosa B Barkardottir
Journal:  Genes (Basel)       Date:  2019-11-01       Impact factor: 4.096

6.  A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient.

Authors:  Ava Kwong; Cecilia Y S Ho; Vivian Y Shin; Chun Hang Au; Tsun Leung Chan; Edmond S K Ma
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

Review 7.  How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?

Authors:  Ashok R Venkitaraman
Journal:  DNA Repair (Amst)       Date:  2019-07-08

8.  BRCA1 Mutational Complementation Induces Synthetic Viability.

Authors:  Joseph Nacson; Daniela Di Marcantonio; Yifan Wang; Andrea J Bernhardy; Emma Clausen; Xiang Hua; Kathy Q Cai; Esteban Martinez; Wanjuan Feng; Elsa Callén; Wei Wu; Gaorav P Gupta; Joseph R Testa; André Nussenzweig; Stephen M Sykes; Neil Johnson
Journal:  Mol Cell       Date:  2020-04-30       Impact factor: 17.970

Review 9.  Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?

Authors:  Davide Angeli; Samanta Salvi; Gianluca Tedaldi
Journal:  Int J Mol Sci       Date:  2020-02-08       Impact factor: 5.923

10.  Helicase-inactivating BRIP1 mutation yields Fanconi anemia with microcephaly and other congenital abnormalities.

Authors:  Lara Kamal; Sarah B Pierce; Christina Canavati; Amal Abu Rayyan; Tamara Jaraysa; Orit Lobel; Suhair Lolas; Barbara M Norquist; Grace Rabie; Fouad Zahdeh; Ephrat Levy-Lahad; Mary-Claire King; Moien N Kanaan
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.